Bavarian Nordic konverterer eksisterende kreditfacilitet til bæredygtighedsrelateret lån
July 01, 2024 02:30 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 1. juli 2024 – Bavarian Nordic meddelte i dag, at selskabets eksisterende uudnyttede syndikerede revolverende kreditfacilitet på DKK 1 mia. er blevet konverteret til et...
Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan
July 01, 2024 02:30 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, July 1, 2024 – Bavarian Nordic today announced the conversion of its existing undrawn DKK 1 billion syndicated revolving credit facility (RCF) into a sustainability-linked loan...
Bavarian Nordic tilslutter sig globalt initiativ i kampen mod mpox i Afrika
June 28, 2024 10:27 ET
|
Bavarian Nordic A/S
Bavarian Nordic vil støtte globalt initiativ for at løse mpox-situationen i Afrika gennem tilsagn om donation af 15.000 doser mpox-vaccineDR Congo har udstedt nødbrugstilladelse for MVA-BN-vaccinen ...
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
June 28, 2024 10:27 ET
|
Bavarian Nordic A/S
Bavarian Nordic is committed to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of mpox vaccineEmergency Use Authorization for the MVA-BN vaccine has...
Bavarian Nordic indsender registreringsansøgning for chikungunyavaccine til de europæiske sundhedsmyndigheder
June 26, 2024 04:25 ET
|
Bavarian Nordic A/S
Myndighedsbehandling af enkelt-dose CHIKV VLP-vaccinekandidat til forebyggende immunisering mod sygdom forårsaget af chikungunyavirus for personer i alderen 12 år og opefter pågår nu både i EU og USA ...
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
June 26, 2024 04:25 ET
|
Bavarian Nordic A/S
Regulatory review of the single-dose CHIKV VLP vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older is now underway in...
Bavarian Nordic indsender registreringsansøgning for chikungunya-vaccine til de amerikanske sundhedsmyndigheder
June 17, 2024 10:21 ET
|
Bavarian Nordic A/S
Selskabet har indsendt sin første registreringsansøgning for CHIKV VLP-vaccinen med henblik på godkendelse af vaccinen til immunisering mod chikungunyavirus for personer i alderen 12 år og...
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
June 17, 2024 10:21 ET
|
Bavarian Nordic A/S
First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and olderRepresents...
Bavarian Nordic indsender supplerende ansøgning til de amerikanske sundhedsmyndigheder om godkendelse af frysetørret koppe- og mpoxvaccine
May 31, 2024 10:33 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 31. maj 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indsendt en supplerende registreringsansøgning til de amerikanske sundhedsmyndigheder, U.S. Food and...
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
May 31, 2024 10:33 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA)...